Stock IXI IXICO PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:04 2024-04-26 am EDT 		5-day change 1st Jan Change
8.625 GBX 0.00% Intraday chart for IXICO plc -1.43% -31.00%
Apr. 15 Ixico inks supply agreement with Life Molecular Imaging for Neuraceq AN
Apr. 15 IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Capitalization 1 23.92 45.68 38.52 16.13 9.187 4.17
Enterprise Value (EV) 1 16.66 37.95 32.43 10.36 5.156 2.77
P/E ratio 55.4 x 48.5 x 25.6 x 16.5 x -7.79 x -1.57 x
Yield - - - - - -
Capitalization / Revenue 3.16 x 4.79 x 4.19 x 1.87 x 1.38 x 0.8 x
EV / Revenue 2.2 x 3.98 x 3.53 x 1.2 x 0.77 x 0.53 x
EV / EBITDA 33.3 x 29.2 x 19.1 x 6.91 x -6.44 x -1.31 x
EV / FCF - - - - -3.1 x -1.03 x
FCF Yield - - - - -32.2% -97.5%
Price to Book - - - - - -
Nbr of stocks (in thousands) 46,902 47,091 48,151 48,151 48,351 48,351
Reference price 2 0.5100 0.9700 0.8000 0.3350 0.1900 0.0862
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Net sales 1 7.561 9.532 9.19 8.643 6.665 5.199
EBITDA 1 0.5 1.3 1.7 1.5 -0.8 -2.121
EBIT 1 0.364 0.856 1.181 0.908 -1.437 -2.864
Operating Margin 4.81% 8.98% 12.85% 10.51% -21.56% -55.09%
Earnings before Tax (EBT) 1 0.366 0.858 1.16 0.885 -1.361 -2.864
Net income 1 0.432 0.952 1.575 1.035 -1.178 -2.664
Net margin 5.71% 9.99% 17.14% 11.98% -17.67% -51.24%
EPS 2 0.009200 0.0200 0.0312 0.0203 -0.0244 -0.0550
Free Cash Flow 1 - - - - -1.661 -2.7
FCF margin - - - - -24.92% -51.93%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 S1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 0.216
Net margin -
EPS 2 0.004300
Dividend per Share -
Announcement Date 5/24/22
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - -
Net Cash position 1 7.26 7.73 6.09 5.77 4.03 1.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - - -1.66 -2.7
ROE (net income / shareholders' equity) - - - - -9.85% -31.1%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 0.52 1.14 2.15 2.25 1.96 0.56
Capex / Sales 6.84% 11.98% 23.44% 25.97% 29.45% 10.69%
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for IXICO plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IXICO PLC Stock IXICO plc
-31.00% 5.19M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IXI Stock
  4. Financials IXICO plc